semaglutide market Liraglutide and Share Report, 2023-2032 Ozempic (Semaglutide) - Semaglutide market

Hellwege, Nicholette D

Novo Nordisk Headquarters: Bagsvrd, Denmark Number of employees: 77,000 Year founded: 1923 Revenue (2025): $42.1 billion Forbes overall rank: 42 In 2025, Novo Nordisk reported full-year sales of about DKK 309.1 billion (roughly $45 billion), a ~6% increase in Danish kroner and ~10% at constant exchange rates, driven mainly by obesity and diabetes semaglutide products Wegovy and Ozempic, though operating profit growth was modest and weighed down by transformation costs and pricing pressures

For instance: Heart disease Pancreatitis Kidney problems Stomach issues Such medications can make things worse

References Semaglutide Microdose (Compounded) Semaglutide Microdose is a lower-strength compounded formulation of the same active ingredient as standard semaglutide, designed to provide a gentler introduction for patients new to GLP-1 therapy or those who experienced side effects at standard doses